title: Possible involvement of protein kinase C activation in differentiation of human umbilical vein endothelium-derived cell into smooth muscle-like cell.
abstract: We previously reported that when deprived of fibroblast growth factor, human umbilical vein endothelium-derived cells (HUVE-DCs) are capable of differentiating into smooth muscle-like cells through activin A-induced, Smad-dependent signaling, and that maintenance of the endothelial-cell phenotype and differentiation into smooth muscle-like cells are reciprocally controlled by fibroblast growth factor-1 and activin A (Ishisaki et al., 2003). Here, we examined how protein kinase C (PKC), which plays pivotal roles in the regulation of cellular proliferation and differentiation in numerous cell types, might affect the above differentiation. We found that phorbol-12-myristate-13-acetate-induced down-regulations of some PKCs accompany suppressions of the expressions of smooth muscle cell markers in HUVE-DCs deprived of fibroblast growth factor. Moreover, the PKC-inhibitors Gö6850 and Gö6983 suppressed the differentiation of HUVE-DCs into smooth muscle-like cells. These results strongly suggest that activation of PKC is involved in the above differentiation.
authors.affiliation: Age Dimension Research Center, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, Japan. ishisaki@cc.gifu-u.ac.jp
authors.forename: Akira
authors.initials: A
authors.lastname: Ishisaki
authors.forename: Hironaka
authors.initials: H
authors.lastname: Tsunobuchi
authors.forename: Keiichi
authors.initials: K
authors.lastname: Nakajima
authors.forename: Toru
authors.initials: T
authors.lastname: Imamura
mesh_terms: D002227:Carbazoles / Q000494:pharmacology; D002273:Carcinogens / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology*; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000502:physiology*; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D008301:Maleimides / Q000494:pharmacology; D032389:Myocytes, Smooth Muscle / Q000502:physiology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014471:Umbilical Veins / Q000166:cytology / Q000502:physiology*
chemical_list: C465664:2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide; D002227:Carbazoles; D002273:Carcinogens; D004791:Enzyme Inhibitors; D007211:Indoles; D008301:Maleimides; D011493:Protein Kinase C; C070515:bisindolylmaleimide I; D013755:Tetradecanoylphorbol Acetate